Reza Zadno, PhD, medical device entrepreneur and health care senior executive joined Avedro in 2016 to lead the company through commercialization after receiving FDA approval for its cross-linking device and drugs in the United States and speed the clinical development of PiXL, a first-in-category, non-surgical procedure for the correction of myopia. Reza brings to Avedro deep expertise in ophthalmology as well as other life science sectors, leveraging his extensive operational and technical experience in multiple highly successful companies. Previously, Reza was the founder, president and CEO of Visiogen (acquired by Abbott), Chairman of the Board at Transcend Medical (acquired by Alcon) and Oraya Therapeutics (acquired by Zeiss). He has also been an advisor to InterWest Partners and Novartis Venture Fund. Reza has a PhD from Ecole Nationale Superieure des Mines de Paris in mechanical properties of materials, speaks 3 languages and has filed more than 100 US patents.